

Special Issue

Diagnosis and Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms

Message from the Guest Editor

This Special Issue focuses on the diagnosis and treatment of gastroenteropancreatic tumors, with world-leading experts in the field providing the readers with contemporary treatment and diagnosis algorithms, as well as a glimpse into novel and evolving treatments. Gastrointestinal pancreatic neuroendocrine neoplasms (GEP-Nets) present many diagnostic and therapeutic challenges due to their relative rarity and complexity. Therefore, the latest findings on biomarkers, peptide receptor-based therapy or imaging therapy, etc., for the treatment of gastroenteropancreatic tumors are exciting. We would like to invite an array of scientific readers to contribute their research to this Special Issue of *Cancers*, dedicated to the generic topic of the diagnosis and treatment of gastroenteropancreatic tumors, such as gastric neuroendocrine tumors, pancreatic neuroendocrine tumors and small intestinal neuroendocrine tumors. We would like to thank you in advance for your enthusiastic participation in this exciting Special Issue of *Cancers*.

Guest Editor

Prof. Dr. Peter Stålberg

Department of Surgery, Uppsala University Hospital, Uppsala University, Uppsala, Sweden

Deadline for manuscript submissions

closed (31 October 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/120291

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)